Why medtech industry must remain creative, not strangled by bureaucracy
This article was originally published in Clinica
Executive Summary
Introducing ever more stringent premarket regulatory controls will not solve device compliance. Instead the process becomes too expensive, too complex and slows the adoption of new beneficial technology.